Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13562417 | 0.80 | P2RX7 (0.41) | KMT2AMAPTTAAR1HTR2CHTR2B | |
| SCHEMBL18762884 | 0.78 | MEN1 (0.50) | HRH3KMT2ATAAR1MEN1HTR2C | |
| SCHEMBL19415197 | 0.78 | KMT2A (0.52) | HRH3CYP1A2CYP2D6KMT2AMAPT | |
| SCHEMBL48241 | 0.77 | TAAR1 (0.47) | KMT2ATAAR1MEN1PNMTIDO1 | |
| SCHEMBL13561345 | 0.76 | POLB (0.41) | KMT2ATAAR1LMNAHTR2CHTR2B | |
| SCHEMBL18762379 | 0.76 | TAAR1 (0.47) | KMT2AMAPTTAAR1MEN1LMNA | |
| SCHEMBL13401237 | 0.75 | HRH3 (0.50) | HRH3CYP1A2CYP2D6KMT2AMAPT | |
| SCHEMBL13562419 | 0.73 | CYP1A2 (0.46) | CYP1A2CYP2D6KMT2ATAAR1LMNA | |
| SCHEMBL13401250 | 0.73 | HRH3 (0.49) | HRH3CYP1A2CYP2D6KMT2AMAPT | |
| SCHEMBL487617 | 0.72 | HRH3 (0.55) | HRH3CYP1A2CYP2D6KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751890-B2 | Heteroaryl derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170107225-A1 | HETEROARYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107225-A1 | HETEROARYL DERIVATIVES AS CFTR MODULATORS | CFTR, ABCB1, ABCD3 | HRH3 3413/4885CYP1A2 2294/4885CYP2D6 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.